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ABSTRACT
TGFβ-ALK5 pro-fibrotic signalling and herpesvirus infections have
been implicated in the pathogenesis and exacerbation of pulmonary
fibrosis. In this study we addressed the role of TGFβ-ALK5 signalling
during the progression of fibrosis in a two-hit mouse model of murine
γ-herpesvirus 68 (MHV-68) infection on the background of pre-
existing bleomycin-induced pulmonary fibrosis. Assessment of total
lung collagen levels in combination with ex vivo micro-computed
tomography (µCT) analysis of whole lungs demonstrated that
MHV-68 infection did not enhance lung collagen deposition in this
two-hit model but led to a persistent and exacerbated inflammatory
response. Moreover, µCT reconstruction and analysis of the two-hit
model revealed distinguishing features of diffuse ground-glass
opacities and consolidation superimposed on pre-existing fibrosis
that were reminiscent of those observed in acute exacerbation of
idiopathic pulmonary fibrosis (AE-IPF). Virally-infected murine fibrotic
lungs further displayed evidence of extensive inflammatory cell
infiltration and increased levels of CCL2, TNFα, IL-1β and IL-10.
Blockade of TGFβ-ALK5 signalling attenuated lung collagen
accumulation in bleomycin-alone injured mice, but this anti-fibrotic
effect was reduced in the presence of concomitant viral infection. In
contrast, inhibition of TGFβ-ALK5 signalling in virally-infected fibrotic
lungs was associated with reduced inflammatory cell aggregates and
increased levels of the antiviral cytokine IFNγ. These data reveal
newly identified intricacies for the TGFβ-ALK5 signalling axis in
experimental lung fibrosis, with different outcomes in response to
ALK5 inhibition depending on the presence of viral infection. These
findings raise important considerations for the targeting of TGFβ
signalling responses in the context of pulmonary fibrosis.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the most progressive and fatal
of all fibrotic conditions, with a median survival of 3 years. The
pathomechanisms involved remain poorly understood, but current
hypotheses propose that this condition arises as a result of repetitive
epithelial injury followed by a highly aberrant wound healing
response in genetically susceptible and aged individuals (reviewed
in Datta et al., 2011). The classical histopathological pattern of
IPF presents as usual interstitial pneumonia (UIP), with evidence
of patchy epithelial damage and hyperplasia combined with
abnormal proliferation of mesenchymal cells, concomitant with
overproduction and disorganized deposition of extracellular matrix
(ECM). Fibrotic foci, the histopathological hallmark of UIP/IPF,
comprise accumulations of fibroblasts and myofibroblasts within an
extensive ECM underlying injured and reparative epithelium, and
are widely considered to represent the leading edge of the fibrotic
response.
Although the aetiology of IPF remains unknown, studies
examining the role of infection in IPF implicate viral infections,
especially human herpesviruses (HHVs), as important contributors
to the initiation and progression of this condition (reviewed in
Molyneaux and Maher, 2013). Current evidence, albeit from small
IPF cohort studies, suggests a role for Epstein-Barr virus (EBV),
human cytomegalovirus (HCMV), human herpesvirus-8 (HHV-8)
and human herpesvirus-7 (HHV-7) in the progression of fibrosis
(Calabrese et al., 2013; Egan et al., 1995; Tang et al., 2003; Vergnon
et al., 1984). Moreover, there is evidence linking viral infection with
the incidence of acute exacerbation of IPF (AE-IPF) (Wootton et al.,
2011), a life-threatening complication that presents as worsening of
dyspnoea and an accelerated decline in lung function (Collard et al.,
2007).
Animal models of fibrosis have established a causal role for viral
infection in the progression of experimental pulmonary fibrosis
(Ashley et al., 2014; McMillan et al., 2008; Mora et al., 2005;
Vannella et al., 2010). Murine γ-herpesvirus 68 (MHV-68) is
closely related to EBV and, like its human counterpart, infects the
respiratory epithelium and establishes life-long latency in the host
(Nash et al., 2001). This viral tropism for alveolar epithelial cells II
(AEC II) contributes to dysregulated epithelial repair and surfactant
abnormalities associated with increased apoptosis and alveolar
collapse (Lawson et al., 2008). Moreover, latent viral infection alters
the phenotype of infected alveolar epithelial cells and fibroblasts,
leading to increased TGFβ production and activation (Stoolman
et al., 2010; Vannella et al., 2010), as well as increased fibroblast
responsiveness to this cytokine, especially in aged mice (Naik et al.,
2011).
Current evidence supports a central role for TGFβ in the
pathogenesis of fibrosis, including human and murine pulmonary
fibrosis (Santana et al., 1995). TGFβ is a potent promoter of
extracellular matrix production and promotes fibroblast-to-
myofibroblast differentiation, as well as epithelial cell apoptosis
(reviewed in Fernandez and Eickelberg, 2012). Multiple approaches
that disrupt either TGFβ activation or signalling through directReceived 20 January 2015; Accepted 26 June 2015
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cytokine inhibition (Giri et al., 1993), Smad3 knockout (Bonniaud
et al., 2004), TGF-βRII receptor knockout (Li et al., 2011), integrin
αvβ6 knockout (Koth et al., 2007; Morris et al., 2003) or antibody
neutralization (Horan et al., 2008) have offered protection in
experimental models of pulmonary fibrosis.
The aim of this study was to further our understanding of the
mechanistic links between MHV-68 infection, TGFβ signalling
and lung fibrosis. We first established and characterized a model
of MHV-68 infection on the background of bleomycin-induced
pulmonary fibrosis using standard endpoints (analysis of total lung
hydroxyproline) and further investigated disease pathophysiology
using ex vivo micro-computed tomography (µCT) scanning of
whole lungs (Scotton et al., 2013). To investigate the potential role
of TGFβ signalling in this model, we employed a highly selective,
ATP-competitive activin receptor-like kinase 5 (ALK5; also known
as TGF-βRI) inhibitor, SB525334, which has a proven therapeutic
effect in single-hit models of experimental pulmonary fibrosis
(Bonniaud et al., 2005; Scotton et al., 2013). Taken together, our
data reveal previously unknown intricacies for the TGFβ signalling
axis in experimental lung fibrosis, with different outcomes observed
in response to ALK5 inhibition depending on the presence or
absence of viral infection. These findings raise potential clinical
considerations for the future targeting of the TGFβ pathway in the
context of pulmonary fibrosis, including IPF.
RESULTS
Two-hit model of MHV-68 infection on the background of
bleomycin-induced fibrosis
In order to establish a two-hit model of MHV-68 infection on the
background of fibrosis, mice were challenged with an
oropharyngeal instillation of bleomycin (25 IU/mouse) on day 0,
followed by an intranasal infection with MHV-68 (1×105 PFU) on
day 14. To further our understanding of the mechanistic links
between MHV-68 infection and TGFβ signalling in this model, the
ALK5 inhibitor (SB525334) was administered therapeutically from
day 15 after bleomycin injury through to the end of the experiment
at day 28.
Total lung collagen was measured by quantifying hydroxyproline
levels by reverse-phase high performance liquid chromatography
(HPLC) (Fig. 1). MHV-68 infection alone [saline (Sal)+MHV68]
had no significant effect on total lung collagen levels when
compared to uninfected control lungs (Sal). Administration of
bleomycin (Bleo) resulted in a doubling of lung collagen
deposition, which was significantly attenuated by SB525334
treatment in the Bleo+SB525334 group (mean±s.e.m. of Bleo vs
Bleo+SB525334, 3.8±0.4 mg vs 2.97±0.14 mg, P=0.04). MHV-68
infection on the background of existing lung fibrosis (Bleo+MHV-
68) did not increase total lung collagen levels compared to the Bleo
group. Interestingly, in the two-hit model, there was no difference in
Fig. 1. The anti-fibrotic effect of TGFβ-ALK5 signalling inhibition is
attenuated in the two-hit model of MHV-68 infection on the background
of pre-existing fibrosis. Total lung collagen was quantified by reverse-
phase HPLC 28 days post-oropharyngeal bleomycin instillation
(corresponding to 14 days p.i. with MHV-68). The ALK5 inhibitor SB525334
was administered according to a therapeutic dosing regimen during the
progressive fibrotic phase (from day 15 post-bleomycin-instillation;
corresponding to 1 day p.i.). MHV-68 infection in saline control lung did not
significantly increase lung collagen levels. SB525334 attenuated lung
collagen accumulation in the single-hit model of lung fibrosis, but the
anti-fibrotic effect of SB525334 was attenuated in the two-hit model of fibrosis
with concomitant infection of fibrotic lung. Data are representative of mean±
s.e.m., n=3 for saline groups and n=8 for bleomycin groups; statistical
analysis, Student’s t-test, *P<0.05.
TRANSLATIONAL IMPACT
Clinical issue
Idiopathic pulmonary fibrosis (IPF) is the most progressive and
devastating form of lung fibrosis, with a median survival of less than 3
years. Episodes of rapid deterioration, termed acute exacerbations (AE),
occur in roughly 10% of individuals with IPF annually, and are a leading
cause of morbidity and mortality. Key features of AE include new
pulmonary changes and abnormalities that are visible on high-resolution
computerized tomography (HRCT) scans; notably, new bilateral ground-
glass abnormalities and consolidation superimposed on a background
IPF. Histological evaluation of AE-IPF reveals interstitial oedema,
hyaline membrane formation and extensive diffuse alveolar damage
and haemorrhage. Although the aetiology and mechanisms of AE-IPF
are not fully elucidated, current evidence links infection with
herpesviruses to the rapid progression of pulmonary fibrosis. TGFβ
has been widely implicated in the pathogenesis of pulmonary fibrosis,
and strategies that interfere with excessive TGFβ signalling or activation
are currently a major focus of therapeutic drug development in this and
other fibrotic conditions. The aim of this study was to employ novel micro-
computed tomography (μCT) imaging in combination with standard
fibrotic end points in order to fully characterize the pathophysiological
responses in a two-hit model of murine γ-herpesvirus 68 (MHV-68)
infection on the background of experimentally induced pulmonary
fibrosis, and to test the therapeutic effect of blocking TGFβ-ALK5
signalling in the presence of concomitant viral infection.
Results
This study revealed that concomitant viral infection on the background of
pre-existing bleomycin-induced fibrosis in mice leads to prominent and
extensive inflammatory changes that are reminiscent of ground-glass
opacities and consolidation reported in individuals with AE-IPF. Blocking
TGFβ-ALK5 signalling by therapeutic dosing with the potent and
selective ALK5 antagonist SB525334 was highly effective in blocking
the progression of fibrosis in the single-hit bleomycin-alone injured
mouse model, but the anti-fibrotic effect of this agent was dramatically
reduced in the presence of concomitant viral infection. In contrast, this
inhibitor was highly effective in attenuating extensive inflammatory cell
infiltration associatedwith concomitant viral infection and it enhanced the
antiviral cytokine response.
Implications and future directions
These studies highlight the pleiotropic nature of the TGFβ-ALK5
signalling axis in pulmonary fibrosis, with different outcomes in
response to ALK5 inhibition depending on the presence of viral
infection. These findings thus raise important considerations for the
future targeting of TGFβ signalling in the context of pulmonary fibrosis:
different outcomes on fibrotic progression are expected in stable IPF
versus AE-IPF associated with viral infection.
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total lung collagen between the Bleo+MHV-68+SB525334 group
compared with the Bleo+MHV-68 group (mean±s.e.m. of Bleo
+MHV-68 vs Bleo+MHV-68+SB525334, 4±1 mg vs 3.5±0.4 mg,
P=0.6). These observations were further confirmed by the Sircol
assay (supplementary material Fig. S1). Taken together, these data
led us to conclude that SB525334 attenuates fibrosis in the single-hit
model but that the therapeutic effect of this inhibitor is largely lost in
the two-hit model.
µCT characterization of the two-hit model
Ex vivo µCT was subsequently used to further investigate the effect
of SB525334 treatment in this two-hit model. Fig. 2 shows
representative 3D volume reconstructions (left panels) with
corresponding mid-lung coronal µCT sections (middle panels) and
magnification of key pathological changes (right panels) for lungs at
day 28. Sal+MHV-68 lungs were indistinguishable from Sal control
lungs, with both groups displaying an equally homogenous
Fig. 2. μCT characterization and
quantification of the pathological changes
in the single- and two-hit models. 3D volume
reconstruction (left panels, dorsal view) and
representative coronal µCT sections (middle
panels) with higher (4×) magnification of the
highlighted insert (right panel). Mice treated
with saline (Sal; A) or Sal+MHV-68 (B) show
normal lung morphology; Bleomycin (Bleo)-
treated mice (C) show dense subpleural fibrotic
lesions, which are attenuated in the Bleo
+SB525334 group (D); Bleo+MHV-68 mice (E)
show evidence of extensive ground-glass
opacities radiating from airways and overlying
areas of dense consolidation; Bleo+MHV-68
+SB525334 mice (F) reveal dense
consolidation with reduced areas of ground-
glass opacities. InForm analysis demonstrates
an increase in the percentage of abnormal lung
area (G) and density (H) in Bleo lungs above
the Sal control (dotted line). No significant
difference was observed between the Bleo and
Bleo+MHV-68 groups. Administration of
SB525334 from day 15 post-bleomycin-
instillation (and 1 day p.i.) significantly
attenuated lung pathology in the Bleo group but
not in the two-hit Bleo+MHV-68 model. The
data are representative of mean±s.e.m., one-
way ANOVA, *P<0.05, **P<0.01, comparison of
all Bleo-challenged groups (n=5).
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appearance with a network of airways in a virtually transparent
parenchyma (Fig. 2A,B). In the Bleo group, peripheral dense fibrotic
lesionswere clearly visible, particularly on the dorsal side of the lungs
(Fig. 2C), as previously reported for oropharyngeal bleomycin
instillation (Lakatos et al., 2006; Scotton et al., 2013). Coronal
sections revealed prominent sub-pleural scarring, interlobular septal
thickening and traction bronchiectasis (Fig. 2C). In Bleo+SB525334
lungs, scarring and fibrosis were noticeably reduced (Fig. 2D). In
contrast, in the two-hit model, lungs displayed extensive areas of
dense consolidation with overlapping diffuse ground-glass opacities
indicative of inflammatory changes concentrated around the airways
(Fig. 2E). SB525334 treatment visibly reduced the ground-glass
appearance in the two-hit model but the fibrotic lesions remained
largely unaffected (Fig. 2F).
Quantification of changes observed in µCT scans
The abnormal lung area and lung density were subsequently
quantified using tissue segmentation analysis of the whole lungs.
Bleomycin injury alone resulted in ∼40% of the total lung volume
being characterized as abnormal; thiswas reduced to∼15% following
SB525334 treatment (Fig. 2G). In the Bleo+MHV-68 group, ∼50%
of the lung volume was categorized as abnormal. SB525334
treatment in this two-hit model only showed a modest therapeutic
effect. Analysis of lung density revealed that total lung density was
increased by fourfold for the Bleo group compared with the Sal group
(Fig. 2H). This increase was reduced by ∼50% in the Bleo+
SB525334 group, confirming the beneficial therapeutic effect of
ALK5 inhibition in the single-hit model (Fig. 2H). The voxel density
score was highest for the Bleo+MHV-68 two-hit lungs and this was
not significantly reduced in the Bleo+MHV-68+SB525334 group.
In order to further investigate differences in lung morphology, we
next performed voxel density distribution analysis for each lung
based on the unsegmented µCT data. The mean number of voxels
per lung at each greyscale density value (0-255) was calculated and
plotted as a histogram (Fig. 3A). Statistically significant differences
in the density voxel distribution between individual experimental
Fig. 3. Voxel density distribution analysis shows
key differences between the single- and two-hit
models. Density distribution histograms show the
mean number of voxels plotted against greyscale
density values (0=air/black, 255=dense tissue/white)
for each experimental group. (A) A shift towards
higher voxel densities is observed for bleomycin
(Bleo)-treated lungs due to Bleo-induced injury, and
a further shift to the right for the two-hit Bleo+MHV-68
group is indicative of additional injury. This density
shift is reduced in the Bleo+SB525334 group,
suggestive of attenuated fibrosis but not in Bleo
+MHV-68+SB525334 lungs. (B) The differences in
proportion of density voxels for each greyscale bin
between Bleo-instilled groups (n=5 animals per
group), which account for the shifts in the histograms,
were analyzed by Student’s t-test at each bin. The
data are shown as graphs of probability (y-axis)
versus greyscale density value (x-axis), with the
significance cut-off set at 0.05 (indicated by the
dotted line). (C-E) Distribution of significantly
different voxel densities was visualized on
representative µCT scans (red pixels): (C) Bleo and
Bleo+SB525334 show voxel localization to fibrotic
lesions; (D) Bleo+MHV-68 and Bleo lungs show
voxel distribution in fibrotic lesions and dispersed
throughout the parenchyma; (E) Bleo+MHV-68 and
Bleo+MHV-68+SB525334 lungs show voxel
distribution dispersed throughout the parenchyma.
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groups were evaluated by a probability t-test (Fig. 3B). A clear
separation in the density distribution was observed between Sal,
Bleo and Bleo+MHV-68 lungs, with a marked shift towards higher
density voxels in the Bleo group, which was further increased in the
Bleo+MHV-68 group.
Significantly different voxel distributions between the Bleo and
Bleo+SB525334 groups fell in the greyscale density range of
100-155; these voxels localized to fibrotic lesions in the Bleo group
(Fig. 3C). Significant increases over a wide voxel range (50-115)
were observed in the Bleo+MHV-68 group compared with Bleo
(Fig. 3D). In the Bleo+MHV-68 lungs, these voxels corresponded
to extensive areas of parenchymawith diffuse ground-glass opacities,
in addition to fibrotic lesions. Treatment with SB525334 had a
significant effect on a very narrow range of voxels (50-65) in the
two-hit group, again indicating the lack of therapeutic effect of
ALK5 inhibition on fibrosis in the two-hit model (Fig. 3E).
Quantification of inflammation in the two-hit model
The lung abnormalities mapped by µCT analysis were subsequently
matched to fibrotic and inflammatory changes identified on
hematoxylin and eosin (H&E) and Martius Scarlet Blue (MSB)-
stained tissue sections (Fig. 4). Histological analysis confirmed
dense patchy fibrosis and collagen deposition in Bleo-injured lungs,
which was reduced in mice treated with SB525334. Bleo+MHV-68
lungs displayed evidence of extensive fibrotic lesions and, notably,
infiltrations of mononuclear inflammatory cells that formed dense
aggregates. We subsequently quantified these inflammatory cell
aggregates (IAs) and found that, consistent with our radiological
findings, there was little evidence of IAs in Sal+MHV68 lungs.
In stark contrast, there were numerous IAs present in the
Bleo+MHV-68 two-hit group and these IAs were significantly
increased compared with all other experimental groups (Fig. 5A).
The number of these IAs was significantly reduced in the two-hit
group treated with SB525334 (mean±s.e.m. of Bleo+MHV-68 vs
Bleo+MHV-68+SB525334, 1±0.25 vs 0.4±0.13 ROI/mm2,P<0.05).
We next measured levels of immunomodulatory mediators in
lung homogenates and report that viral infection in fibrotic lungs
(Bleo+MHV-68) led to a significant increase in lung levels of CCL2
(Fig. 5B), IL-1β (Fig. 5D), TNFα (Fig. 5E) and IL-10 (Fig. 5F)
above the levels detected for Bleo lungs. Treatment with SB525334
did not affect the levels of any of these mediators. In contrast, IFNγ
was only detectable in virally-infected lungs and IFNγ levels were
significantly increased in the Bleo+MHV68+SB525334 group
compared to the Bleo+MHV-68 group (mean±s.e.m. of Bleo+
MHV-68 vs Bleo+MHV-68+SB525334, 55.14±2.7 vs 96.7±
18.6 μg/lung, P<0.05) (Fig. 5C).
Determination of viral gene expression in the two-hit model
It has been previously reported that active viral replication is
required for exacerbation of experimental pulmonary fibrosis
(Ashley et al., 2014; McMillan et al., 2008). We therefore
evaluated the expression of three viral genes encoding the
MHV-68 DNA polymerase and the viral envelope proteins
glycoprotein B and M3. In accordance with previous studies
(Vannella et al., 2010; McMillan et al., 2008), we show that the viral
genes are readily detected in whole lung tissue at the peak of lytic
infection 7 days post-infection (p.i.) (supplementary material
Fig. 2A-C). By 14 days p.i. the MHV-68 infection had entered a
latent phase as demonstrated by decreased levels of viral gene
expression in the lung. Blocking TGFβ signalling with the ALK5
Fig. 4. Histological analysis of the single-
and two-hit models. Representative H&E and
MSB sections (100× original magnification;
scale bars: 600 μm) are shown for each
experimental group as annotated. Saline (Sal)
and Saline+MHV-68 lungs show normal
morphology (A,B); (C) typical examples of the
fibrotic lesions with evidence of collagen
deposition observed in the Bleo group. These
are greatly reduced in Bleo+SB525334 lungs
(D); Bleo+MHV-68 lungs show extensive
fibrotic lesions with collagen deposition and
dense inflammatory cell aggregates that
appear less frequent and more dispersed in
Bleo+MHV-68+SB525334 lungs (E,F, boxed
area is 200× magnification; scale bars:
=300 μm). FB, fibrosis; COL, collagen; IA,
inflammatory cell aggregates.
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inhibitor SB525334 had no impact on viral load in the fibrotic lungs
(Fig. 6A-C).
Splenomegaly, a reliable surrogate indicator of herpes virus latent
infection (Nash et al., 2001), was evident 14 days p.i.
(supplementary material Fig. S2D). In all virally-infected mouse
groups, spleen weight was significantly increased when compared
to the saline- or bleomycin-only control groups (Fig. 6D).
Moreover, splenomegaly was further increased in the Bleo+
MHV68 double-hit group compared to single-hit groups, whereas
SB525334 treatment significantly reduced spleen weights.
DISCUSSION
This study aimed to investigate the effect of blocking TGFβ-ALK5
signalling on the progression of lung fibrosis in the presence of
Fig. 5. ALK5 inhibition attenuates inflammatory cell aggregates and enhances IFNγ levels in the two-hit model of MHV-68 infection on a background of
pulmonary fibrosis. (A) Inflammatory aggregates (IAs) were significantly increased in bleomycin- andMHV-68-injured lungswhen compared to other bleomycin-
challenged groups (n=5). SB525334 treatment reduced the number of IAs, quantified and expressed as region of interest per lung (ROI/mm2, mean±s.e.m., five
tissue sections per mouse). Levels of inflammatory and immunomodulatory markers were measured in lung homogenates: CCL2 (B), IFNγ (C), IL-1β (D), TNFα
(E), IL-10 (F); representative of mean±s.e.m., n=3 for saline groups and n=8 for bleomycin groups. One-way ANOVA, *P<0.05, **P<0.01, ***P<0.001.
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concurrent viral infection. We report that MHV-68 viral infection of
the fibrotic lung did not increase lung collagen deposition above the
levels observed in the bleomycin-alone injured mice, but instead led
to the marked accumulation of inflammatory cells, which persisted
for at least 14 days p.i. In contrast, saline control lungs inoculated
with MHV-68 showed normal architecture. The potent and highly
selective TGFβ-ALK5 inhibitor SB525334 (Grygielko et al., 2005)
attenuated fibrosis in the single-hit bleomycin model. In contrast,
TGFβ-ALK5 inhibition did not significantly block collagen
accumulation in the two-hit model but led to a marked reduction
in inflammatory cell infiltrates and an enhanced the anti-viral
cytokine response. Taken together, these data show for the first time
that the therapeutic effect of TGFβ-ALK5 inhibition in lung fibrosis
is curtailed in the presence of concurrent viral infection.
µCT analysis reveals key differences in morphological
features between the single- and two-hit models, and the
therapeutic effect of ALK5 inhibition
The traditional collagen endpoint measurement used to evaluate
fibrosis, based on total lung hydroxyproline levels, has a relatively
limited signal window and does not provide information regarding
the specific spatial distribution of fibrotic lesions or other potential
pathophysiological changes in the injured lung. To complement our
biochemical analysis of lung collagen accumulation, we employed
ex vivo μCT to further characterize the pathological changes in the
fibrotic lung with and without concomitant viral infection. As well
as providing information regarding the spatial distribution of
fibrotic lesions, whole-lung µCT scanning avoids the potential
sampling error associated with standard histological analysis of
tissue sections. This technology has successfully been applied to the
ex vivo investigation of lung architecture (Thiesse et al., 2010;
Vasilescu et al., 2012) and, more recently, as an endpoint for
evaluating fibrosis in single-hit models of fibrosis, based on either
bleomycin or adenoviral overexpression of TGFβ (Rodt et al., 2010;
Scotton et al., 2013). In agreement with previous data from our
laboratory (Scotton et al., 2013), µCT analysis accurately
differentiated dense fibrotic lesions associated with bleomycin
injury from normal lung morphology. µCT analysis of virally-
infected fibrotic lungs revealed diffuse ground-glass opacities and
dense consolidation radiating from the bronchovascular bundles, in
addition to bleomycin-induced fibrotic lesions. These radiological
features are highly reminiscent of those reported in patients with
AE-IPF (Collard et al., 2007).
Matching µCT analysis with the histological analysis of the same
lungs confirmed that high-density areas corresponded to fibrotic
tissue and collagen deposition. The dispersed inflammatory changes
evident on µCT scans of virally-infected fibrotic lungs were
associated with mononuclear cell aggregates localized around the
Fig. 6. Detectionofviralgenes in the lungandsplenomegaly indicateongoingMHV-68 infection.Viral geneexpressionwasdetected in lung tissue14 dayspost
infection. The viral genes measured included (A) gB, (B) DNApol and (C)M3. Data are representative of mean±s.e.m., n=3 for saline groups and n=8 for bleomycin
groups. One-way ANOVA, **P<0.01. (D) Splenomegaly is detected in all virally-infected groups. Data are representative of mean±s.e.m., n=5 for saline groups and
n=13 for bleomycin groups. One-way ANOVA, ***P<0.001 compared to non-infected groups; +P<0.05, ++P<0.01 comparison within virally-infected groups.
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airways and vasculature. Subsequently, the use of InForm pattern-
recognition software was validated in this two-hit model to quantify
the changes observed throughout the µCT scans of thewhole lungs. It
was noted that InForm software accurately highlighted fibrotic lesions
inBleo lungs,whereas, in the two-hitmodel, inflammationwas found
to extensively overlap with fibrosis and hence the ‘abnormal lung’
fraction encompassed both types of changes in this model. The µCT
analysis confirmed the collagen biochemical data and led us to
conclude that, although ALK5 inhibition was effective in preventing
fibrotic progression in the single-hit model, this therapeutic effectwas
attenuated in the two-hit model. Density distribution analysis led us to
further postulate that SB525334 primarily targeted inflammatory cell
infiltration (lower density voxels) rather than the fibrotic (high density
voxels) response in the two-hit model.
In our study we did not demonstrate an increase in lung collagen
accumulation following MHV-68 infection on the background of
pre-existing fibrosis. This is not a universal finding, and others
have reported exacerbation of fibrosis by MHV-68 in the context
of FITC and bleomycin models of lung fibrosis (Ashley et al.,
2014; McMillan et al., 2008). There could be several potential
explanations, including intrinsic differences between the initiating
fibrogenic insults as well as their route of administration. FITC is a
fine particle that is deposited in the lung and leads to focal chronic
inflammation and fibrosis (Moore andHogaboam, 2008). In contrast,
bleomycin causes initial epithelial injury by direct DNA damage and
oxidative stress, which in turn triggers a robust inflammatory
response leading to inflammatory cell recruitment and vascular leak
(Degryse and Lawson, 2011). Increased TGFβ activity by day-14
post-injury is associated with the development of extensive patchy
fibrosis (Degryse and Lawson, 2011). The route of administration of
bleomycin is known to influence the spatial distribution and
evolution of fibrotic lesions, with intratracheal administration
resulting in localized bronchiocentric lesions and oropharyngeal
administration, as used in our study, causing diffuse peripheral,
subpleural lesions (Scotton and Chambers, 2010). Furthermore,
whereas the intratracheal model of bleomycin-induced fibrosis
resolves over time (Degryse et al., 2010), recent evidence from our
laboratory demonstrated that the oropharyngeal mode of bleomycin
instillation leads to persistent fibrosis and collagen deposition with
little evidence of restoration of lung architecture up to at least
6 months post-injury (Scotton et al., 2013). These key differences
between models might be crucial in terms of determining the
subsequent effect of MHV-68 infection on the progression of the
fibrotic response. In addition, we addressed the possibility that the
differences between the reported studies could have arisen fromusing
different methods of collagen quantification. In agreement with our
HPLC data, standard Sircol colorimetric assay confirmed the lack of
exacerbated lung collagen accumulation in our model. In contrast, all
studies agree thatMHV-68 infection triggered a robust and persistent
inflammatory response on a background of pre-existing fibrosis.
ALK5 inhibition targets inflammatory cell infiltration in the
two-hit model
MHV-68 infection alone leads to the long-term release of
immunomodulatory mediators by resident and recruited cells in the
lung, including: TNFα by mesenchymal cells, B cells and alveolar
macrophages; CCL2 and IFNγ by alveolar macrophages; and IFNγ
and IL-10 byT cells (Sarawar et al., 1996; Stoolman et al., 2010). Our
two-hit model clearly demonstrates that, in the event of infection
concomitant with pre-existing fibrosis, the inflammatory response is
exacerbated, persistent and associated with a further increase in the
accumulation of mediators that might also perpetuate the profibrotic
milieu. CCL2 is readily detected in the sera and bronchoalveolar
lavage fluid of IPF patients (Baran et al., 2007; Suga et al., 1999) and
promotes fibrocyte and inflammatory cell recruitment (Moore et al.,
2005) aswell as collagen production by fibroblasts (Kimet al., 2014).
In models of MHV-68-mediated exacerbation of FITC-induced
fibrosis (McMillan et al., 2008) and fibrosis in latently infected lungs
(Vannella et al., 2010), high levels of CCL2 and CCL12 are detected
in virally-infected fibrotic lungs. Overexpression of IL-1β in vivo
leads to acute alveolar and parenchymal inflammation that progresses
into interstitial fibrosis with accumulation of fibroblasts and
myofibroblasts in the lung (Kolb et al., 2001). Similarly,
overexpression of TNFα in rat lungs leads to acute inflammation
and fibrosis (Sime et al., 1998). Overexpression of IL-10 has also
been linked to the development of pulmonary fibrosis in vivo (Sun
et al., 2011). Although current evidence suggests that TGFβ is an
important driver of lung collagen accumulation during days 14 to 28
post-bleomycin in the single-hit model (Scotton et al., 2013), it is
plausible that, in the two-hit model, the TGFβ-independent, additive
profibrotic actions of these mediators perpetuate ECM deposition
and hence override the antifibrotic effect of SB525334.
In contrast to the lack of therapeutic effect of ALK5 inhibition on
lung collagen accumulation in the two-hit model, the Bleo+MHV-68
infected lungs harboured the highest number of inflammatory
aggregates (IAs) compared with all other experimental groups, and
this parameter was reduced in response to ALK5 inhibitor treatment.
TGFβ plays a key immunomodulatory role, including inhibition of
CD4 T-cell differentiation, IFNγ production, induction of regulatory
T cells and inhibition of antigen-presenting-cell function (Odeberg
and Söderberg-Nauclér, 2001). In models of Herpes simplex virus-1
(HSV-1) infection, inhibition of TGFβ signalling in immune cells
leads to the expansion of natural killer (NK) cells, increased IFNγ
production and hence better control of viral infection, which in turn is
associatedwith reduced immune cell infiltration at the site of infection
(Allen et al., 2011). Moreover, inhibition of TGFβ signalling
decreases the viral capacity to establish latency and reduces the
number of immune cells infiltrations into the primary site of infection
as well as to the site of latency (Allen et al., 2011). In bone-marrow-
transplantation models, latent MHV-68 infection leads to chronic and
persistent pneumonitis and fibrosis, which is associated with the
accumulation of macrophages and the influx of neutrophils and
lymphocytes into the lung, with the latter being dominated by CD8
and CD4 T cells (Coomes et al., 2011). Importantly, blocking TGFβ
signalling in T cells leads to an enhanced antiviral responses and
attenuation of inflammation and fibrosis (Coomes et al., 2010, 2011).
Consequently in our two-hit model, ALK5 inhibition reduced the
number of IAs in the lung and attenuated splenomegaly. Interestingly,
these responses were not associated with any reduction in viral gene
expression in the lung; rather, they were associated with increased
levels of IFNγ in the virally-infected fibrotic lungs treated with the
TGFβ-ALK5 inhibitor. IFNγ does not play a direct role in viral
clearance from the lung (Dutia et al., 1997) but it is a key cytokine
involved in antiviral immunity, essential for CD8 T-cell-mediated
responses during acute lytic infection and for CD4 T-cell-dependent
control of persistent infection (Christensen et al., 1999). IFNγ-
receptor-deficient mice show increased perivascular accumulations of
immune cells, primarily B cells, in response to MHV-68 infection
(Lee et al., 2009). It is plausible that the increase in IFNγ levels is
associated with the decrease in IAs observed in our study. This might
actually be beneficial to the host, because viral load and disease
severity are often neither linear nor indeed associated. The
immunopathology associated with the viral infection is often more
damaging than the virus itself, and, in the case of γ-herpesviruses, this
1136
RESEARCH ARTICLE Disease Models & Mechanisms (2015) 8, 1129-1139 doi:10.1242/dmm.019984
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
immunopathology is associated with Th1-type cytokine expression,
inflammation and bystander tissue damage (Nash et al., 2001).
Antiviral therapies have been shown to be beneficial in a subset of IPF
patients with evidence of EBV infection (Egan et al., 2011), and
attenuate fibrosis resulting from chronic MHV-68 infection in animal
models (Mora et al., 2007). Our results point to an interesting prospect
of combining anti-TGFβ and antiviral therapies as a potential
treatment for pulmonary fibrosis.
Furthermore, the balance between the lytic and latent phases of
infection is also likely to influence the progression of fibrosis. In our
studies we confirmed the switch from lytic phase (7 days p.i.) to the
latent phase (14 days p.i.) by measuring the spleen weights and viral
gene expression in the lungs. To the best of our knowledge, this is the
first report evaluating the progression of fibrosis in the two-hit model
at 14 days p.i., which could be another explanation for the lack of
exacerbation of collagen deposition. Previous studies (Ashley et al.,
2014; McMillan et al., 2008) measured collagen deposition at 7 days
p.i., at the height of the extremely cytotoxic and inflammatory lytic
phase. Another study reported that latent MHV-68 infection induced
a pro-fibrotic phenotype in lung tissue (Stoolman et al., 2010) and
showed exacerbated fibrotic responses in the latently infected lungs
(Vannella et al., 2010). This highlights the need for further
longitudinal studies to assess the relative contributions of
herpesvirus viral replication, latency and specific host responses on
disease severity and concomitant pulmonary fibrosis.
Conclusions and implications
In conclusion, we report that MHV-68 infection on the background
of pre-existing fibrosis leads to a robust and persistent inflammatory
response that is reminiscent of ground glass opacities and
consolidation reported in patients with AE-IPF. Targeting TGFβ-
ALK5 signalling in the fibrotic lung prevents further progression of
fibrosis in the single-hit model but this effect is attenuated in the
presence of concurrent viral infection. In contrast, inhibiting TGFβ-
ALK5 signalling in this context increases the levels of the antiviral
cytokine IFNγ and reduces inflammatory cell infiltration. These
observations highlight the importance of the pleiotropic nature of
TGFβ-ALK5 signalling in immune and antiviral responses in
determining the anti-fibrotic effect of TGFβ-ALK5 inhibition in the
presence of viral infection. These findings have potential important
therapeutic implications in terms of targeting this signalling axis in
human fibrotic lung disease.
MATERIALS AND METHODS
MHV-68 infection on the background of pulmonary fibrosis
All studies were ethically reviewed and performed in accordance with the
UK Home Office Animals for Scientific Procedures Act 1986. C57BL/6
male mice between 10 and 12 weeks of age (Charles River Laboratories,
UK) were administered bleomycin (25 IU/mouse in 50 μl of sterile 0.9%
saline) or saline by oropharyngeal instillation as previously described
(Lakatos et al., 2006).
Two weeks after bleomycin instillation, mice were anaesthetised by
intraperitoneal injection of ketamine (80 mg/kg body weight) and xylazine
(8 mg/kg body weight). 1×105 plaque forming units (PFUs) of MHV-68
(ATCC, Manassas, VA, USA) suspended in 20 μl sterile saline were
inoculated intranasally. Mice were sacrificed 7 or 14 days p.i. by
intraperitoneal injection of pentobarbitone and severing of the abdominal
inferior vena cava.
ALK5-inhibitor study
The highly selective ALK5 inhibitor SB525334 (Grygielko et al., 2005) was
a kind gift from Novartis, Horsham, UK. The compound (30 mg/kg body
weight in 100 μl acidified saline/0.2% Tween 80 pH 4.1) or vehicle
(acidified saline/0.2% Tween 80 pH 4.1) was administered from day 15
post-bleomycin-instillation, which corresponds to 1 day p.i., twice daily by
oral gavage for the remaining duration of the experiment. Treatment
combinations are summarized in Table 1.
For measurements of total collagen and inflammatory mediators, the
lungs were snap-frozen in liquid nitrogen, weighed and pulverized to
homogeneity. For μCT, histological and immunohistochemical analysis, the
lungs were insufflated with 4% paraformaldehyde at a constant pressure
of 20 cm H2O, fixed for 24 h then stored in 70% ethanol. Spleens were
snap-frozen in liquid nitrogen and weighed.
Determination of total lung collagen
Total lung collagen was calculated by measuring hydroxyproline content in
aliquots of pulverized lung. Hydroxyproline was quantified by reverse-
phase HPLC of NBD-Cl-derived acid hydrolysates of the pulverized lung
and the value used to calculate total lung collagen based on the average
hydroxyproline content of collagen (12.2%).
Total lung collagen was also measured using the Sircol assay (Biocolor
Ltd, UK) according to the manufacturer’s instructions. Briefly, a small
quantity of pulverized lung was accurately weighed and acid-pepsin
extracted. The quantity of collagen was calculated in mg per lung.
Micro-computed tomography (μCT) imaging
Insufflated lungs were incubated for 2 h each in increasing concentrations
of ethanol (70%, 80%, 90%), then 100% ethanol overnight before being
transferred to 100% hexamethyldisilazane for another 2 h and then air-
dried. Lungs were scanned in a SkyScan 1072 μCT scanner (SkyScan,
Kontich, Belgium) at 40 kV/100 μA, without a filter, using two frame
averaging at a 0.49° angular rotation step size, and a voxel size set to
12.8 µm with typical Modulation Transfer Function (MTF) of around 10%;
spatial resolution was in the region of 20-30 μm. Scan time was around
10 min, allowing high-resolution visualization and good throughput.
Reconstruction was carried out with the SkyScan NRecon software
(SkyScan, Kontich, Belgium). Also see Scotton et al. (2013) for further
details.
Table 1. Summary of experimental groups
Experimental group
Treatment
Total mice
per group End-point analysisBleomycin MHV-68 SB525334
Sal − − − 5 Biochemistry: 3; µCT/histology: 2
Sal+SB525334 − − + 5 Biochemistry: 3; µCT/histology: 2
Sal+MHV-68 − + − 6 Biochemistry: 4; µCT/histology: 2
Sal+MHV-68+SB525334 − + + 6 Biochemistry: 4; µCT/histology: 2
Bleo + − − 13 Biochemistry: 8; µCT/histology: 5
Bleo+SB525334 + − + 13 Biochemistry: 8; µCT/histology: 5
Bleo+MHV-68 + + − 13 Biochemistry: 8; µCT/histology: 5
Bleo+MHV-68+SB525334 + + + 13 Biochemistry: 8; µCT/histology: 5
On day 0, mice received bleomycin at a dose of 25 IU/mouse or saline via the oropharyngeal route. On day 14, mice were anaesthetised and inoculated
intranasally with MHV-68 (1×105 PFU) or saline. From day 15, mice received SB525334 at a dose of 30 mg/kg body weight or vehicle treatment (acidified saline/
0.2% Tween 80 pH 4.1), twice daily through oral administration (per os). Final n numbers are given in the end-point analysis column.
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μCT image analysis
Tissue segmentation analysis was performed using InForm™ software
(PerkinElmer, UK) as previously described (Scotton et al., 2013). The
software training algorithm was set to discriminate between normal versus
abnormal lung and gate out any non-lung tissue as tested on three
representative μCT sections (8-bit greyscale) from each animal in the study
until over 90% accuracy was achieved. Saline control and Bleo+MHV-68
lungs were set as a standard for normal and abnormal lung categories,
respectively. All μCT sections (∼900 sections per lung) were subsequently
segmented using the same algorithm on a medium sample area at fine
resolution. The output measurements were pixel area and pixel density for
each category that were then compiled into a composite measurement of
abnormal lung volume expressed as a percentage of total lung volume, and
greyscale density expressed as total lung density.
Voxel density distribution analysis
Frequency distribution of voxel densities in unsegmented lung was analyzed
by generating composite 256-colour greyscale histograms (from 0=black to
255=white). The mean number of voxels in each bin (1 greyscale unit wide)
was calculated along with statistical analysis of differences between the
experimental groups.
Histology
Paraformaldehyde-fixed lungs were dehydrated and embedded in paraffin
wax blocks. For standard histological processing, 3-5 μm paraffin sections
were mounted on polylysine-coated glass slides and dewaxed. Hematoxylin
and eosin (H&E) and modified trichrome (Martius Scarlet Blue [MSB])
staining was performed using an automated Sakura Tissue-Tek DRS 2000
Multiple Slide Stainer. All sections were subsequently scanned on a
Nanozoomer and images were captured using NDP.view v.1.2.36 (both
from Hamamatsu Corporation, Hamamatsu, Japan).
Direct comparisons between μCT and histology were performed on the
same set of lungs: post-μCT lungs were rehydrated through an ethanol
gradient (100%, 90%, 80% and 70% for 2 h in each) prior to standard
processing as above.
Inflammatory cell aggregate (IA) counts
IAs were identified and quantified in H&E sections using Nuance® FX
Multispectral Tissue Imaging Software (PerkinElmer, UK). The software
unmixed and enhanced the areas of intense haematoxylin staining
that corresponded to IAs and quantified them as regions of interest per area
of the lung section (ROI/mm2; five whole histological sections per animal).
Measurements of inflammatory markers
Lung powders were homogenized in PBS/1% Triton X (Sigma, UK)/
proteinase inhibitor cocktail (Roche, UK) using a freeze-thaw cycle. CCL2
DuoSet ELISA Development kits were purchased from R&D Systems,
USA, and used according to the manufacturer’s instructions. The optical
density was measured using a plate reader (MultiskanMCC/340, Titertek) at
dual wavelength A1: 450 nm and A2: 540 nm. Mouse pro-inflammatory
Panel 1 V-Plex Plus Kit was purchased from Meso Scale Discovery
(Rockville, MD, USA) for quantification of the following ten cytokines that
are important in infection and inflammation: IFN-γ, IL-1β, IL-2, IL-4, IL-5,
IL-6, KC/GRO, IL-10, IL-12p70 and TNF-α. The kit was used according to
manufacturer’s protocol. Sector Imager 600 MSD plate reader and MSD
Discovery Workbench software were used to record and analyze the results.
RT-PCR for viral mRNA
TotalRNA from frozenpowdered lung tissuewas isolatedwithTRIzol reagent
as per the manufacturer’s protocol (Invitrogen). RNA was DNase-treated
using a DNAfree kit (Ambion). Real-time RT-PCR was conducted using the
Platinum SYBR Green qPCR SuperMix UDG (Invitrogen, UK) with cycling
conditions as follows: 1 cycle of 50°C for 2 min and 95°C for 2 min; 45 cycles
of 95°C for 5 s, 55°C for 5 s and 72°C for 15 s. The specificity of the PCR
product was confirmed by melting-curve analysis. The gB, DNApol and M3
primer sequenceswere previously published (McMillan et al., 2008). For each
gene, crossing point (Cp) valueswere determined from the linear region of the
amplification plot and normalized by subtraction of the geometric mean of the
crossing point (Cp) values for two housekeeping genes: ATP synthase 5B
(ATP5B) and calnexin (CANX), identified by GeNorm analysis as the most
stable housekeeping genes for this study. Relative expression was
subsequently calculated using the 2-ΔCp approach. All primers and
GeNorm kits were purchased from Primer Design (Southampton, UK).
Statistical analysis
All data are presented as mean values±s.e.m., unless indicated otherwise.
Statistical analysis was performed between two treatment groups by
Student’s t-test, and between multiple treatment groups by one-way analysis
of variance (ANOVA), using Graphpad Prism 5 software. A P-value of
<0.05 was considered significant.
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